Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Matthew Crowther, Beckman Coulter Diagnostics, on Emerging Resistance
In this video, Matthew Crowther, the Northern Europe Sales Manager at Beckman Coulter Diagnostics, discusses […]
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
PTC Therapeutics has announced that the primary endpoint was achieved in the APHENITY, Phase 3 […]
Keegan Nees, IMMY, on Fungal Infection Diagnostics
We caught up with Keegan Nees, a Product Marketing Strategist from IMMY, at ECCMID, who discusses […]
FzioMed Announces Addition of Industry Veteran to its Board of Directors
FzioMed, a global leading surgical biomaterials company focused on spine, orthopedic, peritoneal and gynecological surgery, […]
Researchers Reveal Newfound DNA Repair Mechanism
A new study adds to an emerging, radically new picture of how bacterial cells continually […]
NHS Rolls Out New ‘Lifeline’ Combination Therapy for Hundreds of Women With Womb Cancer
Hundreds of women with advanced womb cancer in England are to be offered a new […]
Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer
Coeptis Therapeutics, a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today the […]
Siren Biotechnology Launches to Pioneer Universal AAV Immuno-Gene Therapy™ for Cancer
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy, a revolutionary new treatment modality for cancer, […]
IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
IN8bio, a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced […]
Lynk's LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis
Lynk Pharmaceuticals, an innovative clinical-stage company, announced that the Phase II clinical trial of LNK01001 […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more